ClinicalTrials.gg
RecruitingNCT06584409Updated Sep 30, 2026

Migraines Accepted Laser Acupuncture Compared in Blood Test of MMP2 and CGRP

An interventional study of Laser Pen and Observation in Headache, Migraine, sponsored by Taichung Veterans General Hospital. Recruiting at 1 site in Taiwan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Taichung Veterans General Hospital · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.
Updated Sep 30, 2026Primary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies in Migraine Disorders with a site in Taiwan — 9 open to participants now, 13 under way, 2 of them phase 3. Migraine Disorders · Taiwan.

Planned enrollment
20th of 25
60 · median 140
Started
2025
with 2 others
No phase
11 of 28
5 open now
Primary completion
2027-11
later than 10 of 12 live
Registered
24th of 28
by date
Lead sponsor
3 of 28
Taichung Veterans General Hospital

Among the 28 studies in Migraine Disorders with a site in Taiwan, this one is the 20th largest by planned enrollment of the 25 interventional ones that give a count, is one of 3 that started in 2025, is one of 11 with no phase, reaches primary completion later than 10 of the 12 other live ones, and was the 24th registered.

Migraine Disorders

1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

9 of the 28 studies in Migraine Disorders with a site in Taiwan are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Migraine Disorders with a site in Taiwan, or all of them as a file.
02

Study summary

Aims:

To investigate the efficacy of laser-acupuncture for the severity of primary headache and comorbidities, and the Lab data examination.

Methods:

In this hospital-based prospective single blind randomized sham-controlled study, patients over 18 years old with primary headache will be randomly divided into two treatment arms including laser-acupuncture and sham-controlled group. The expected laser-acupuncture protocol will be bilateral BL2, GB20, EX-HN5, GB8, LI4, LR3 and midline EX-HN3 in totally eight sessions at the first month. In the sham-laser-acupuncture group, patients will receive eight sessions of laser-acupuncture for free after unblinding. We expected to track patients for at least half year. The diagnosis and classification of headache was evaluated using the ICHD-3 criteria. The severity of headache was evaluated using Migraine Disability Assessment (MIDAS) and headache diary provided by Taiwan Headache Society. The co-primary efficacy end points are change in migraine days per month and variation of MIDAS. The secondary end point is the reducing of the severity of comorbidities including headache related anxiety and depression, and both of the quality of life and sleep.

In addition, patients' characteristics will be investigated as follows:

  1. Sociodemographic factors (ethnicity, age, sex, body weight, BMI, blood pressure)
  2. Headache related parameters (onset, duration, pain scale, current medication for headache, menstrual cycle)
  3. Anxiety, evaluate by Hospital Anxiety and Depression Scale (HADS)
  4. Depression, evaluate by Beck's Depression Inventory
  5. Quality of life, evaluate by 36-Item Short Form Survey (SF-36)
  6. Quality of sleep, evaluate by Pittsburgh Sleep Quality Index (PSQI)
  7. Aura of headache
  8. Episodic or chronic headache (If patient diagnosed as migraine.)
  9. Nausea, vomiting, photophobia, phonophobia (If patient diagnosed as migraine.) During the following time, we will need the patient's blood samples four times, each times 20cc, all need 80cc for Lab test of MMP2, CGRP, substance P, beta-endorphin.

Importance:

In our hospital, we perform laser-acupuncture for patients with headache for several years. A prospective randomized controlled study is the key tools to establish the efficacy of laser-acupuncture for primary headache, and the Lab data with MMP2, CGRP, substance P, beta-endorphin for approval. Look forward to help improve therapeutic strategies in clinical practice.

Read the detailed description

Headache is one of the most common complaints encountered in medical institution as known as an almost universal human experience. Approximately 65% of headaches are classified as primary, which was a composite of migraine, tension-type headache, trigeminal autonomic cephalalgia and other primary headaches according to the third edition of the International Classification of Headache Disorders (ICHD-3). Primary headaches encompass a heterogeneous group of neurologic disorders and might be bothersome for patients.

It's well established that acupuncture can be considered a treatment option for migraine prevention. The efficacy of laser-acupuncture is similar to acupuncture, and laser-acupuncture is a non-invasive therapeutic approach and safety. It could reduce the risk of hemorrhage, infection and needle phobia. However, the efficacy of laser-acupuncture in primary headache remains inconclusive.

MMP2, CGRP, substance P, beta-endorphin are new Lab examination for following up the patients suffered from migraine.

Aims:

To investigate the efficacy of laser-acupuncture for the severity of primary headache and comorbidities, and the Lab data examination.

Methods:

In this hospital-based prospective single blind randomized sham-controlled study, patients over 18 years old with primary headache will be randomly divided into two treatment arms including laser-acupuncture and sham-controlled group. The expected laser-acupuncture protocol will be bilateral BL2, GB20, EX-HN5, GB8, LI4, LR3 and midline EX-HN3 in totally eight sessions at the first month. In the sham-laser-acupuncture group, patients will receive eight sessions of laser-acupuncture for free after unblinding. We expected to track patients for at least half year. The diagnosis and classification of headache was evaluated using the ICHD-3 criteria. The severity of headache was evaluated using Migraine Disability Assessment (MIDAS) and headache diary provided by Taiwan Headache Society. The co-primary efficacy end points are change in migraine days per month and variation of MIDAS. The secondary end point is the reducing of the severity of comorbidities including headache related anxiety and depression, and both of the quality of life and sleep.

In addition, patients' characteristics will be investigated as follows:

  1. Sociodemographic factors (ethnicity, age, sex, body weight, BMI, blood pressure)
  2. Headache related parameters (onset, duration, pain scale, current medication for headache, menstrual cycle)
  3. Anxiety, evaluate by Hospital Anxiety and Depression Scale (HADS)
  4. Depression, evaluate by Beck's Depression Inventory
  5. Quality of life, evaluate by 36-Item Short Form Survey (SF-36)
  6. Quality of sleep, evaluate by Pittsburgh Sleep Quality Index (PSQI)
  7. Aura of headache
  8. Episodic or chronic headache (If patient diagnosed as migraine.)
  9. Nausea, vomiting, photophobia, phonophobia (If patient diagnosed as migraine.) During the following time, we will need the patient's blood samples four times, each times 20cc, all need 80cc for Lab test of MMP2, CGRP, substance P, beta-endorphin.

Importance:

In our hospital, we perform laser-acupuncture for patients with headache for several years. A prospective randomized controlled study is the key tools to establish the efficacy of laser-acupuncture for primary headache, and the Lab data with MMP2, CGRP, substance P, beta-endorphin for approval. Look forward to help improve therapeutic strategies in clinical practice.

03

Conditions studied

  • Headache, Migraine

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Migraine patient under the diagnosis and classification of headache was evaluated using the ICHD-3 criteria.

Exclusion criteria

Exclusion Criteria:

  • Age under 18 years old
  • Pregnancy
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Laser treatment

    CM patients with unsatisfactory pharmacological effects receive laser acupuncture for 8 sessions that spanned 4 weeks. Laser stimulation energy of 4.5 J for 30 seconds at each of the following acupoints: bilateral Cuanzhu (BL2), Fengchi (GB20), Taiyang (EX-HN5), Shuaigu (GB8), Hegu (LI4), Taichong (LR3) and midline Yintang (EX-HN3)

    Device: Laser Pen

  • Sham comparator
    Sham treatment

    CM patients with unsatisfactory pharmacological effects receive sham treatment for 8 sessions that spanned 4 weeks. Sham treatment had no laser output.

    Other: Observation

Interventions

  • DeviceLaser Pen

    Laser stimulation energy of 4.5 J for 30 seconds at each of the following acupoints: bilateral Cuanzhu (BL2), Fengchi (GB20), Taiyang (EX-HN5), Shuaigu (GB8), Hegu (LI4), Taichong (LR3) and midline Yintang (EX-HN3)

  • OtherObservation

    Sham treatment with no laser output, stimulate the same acupoints as laser acupuncture group as follows: 30 seconds at bilateral Cuanzhu (BL2), Fengchi (GB20), Taiyang (EX-HN5), Shuaigu (GB8), Hegu (LI4), Taichong (LR3) and midline Yintang (EX-HN3) After 6 months followed up, the sham group received truely Laser stimulation energy of 4.5 J for 30 seconds at each of the following acupoints: bilateral Cuanzhu (BL2), Fengchi (GB20), Taiyang (EX-HN5), Shuaigu (GB8), Hegu (LI4), Taichong (LR3) and midline Yintang (EX-HN3), and followed up for another 3 months.

06

What researchers measure

Primary outcomes

  1. cGRP

    change in cGRP from baasline and each follow-up time point

    Time frame: 12 weeks, 24 weeks, 36 weeks

  2. MMP2

    change in MMP2 from baasline and each follow-up time point

    Time frame: 12 weeks, 24 weeks, 36 weeks

Secondary outcomes

  1. Difference in the number of headache days per month

    change in monthly migraine days (MMD) from baseline and each follow-up time point

    Time frame: 12 weeks, 24 weeks, 36 weeks

  2. Difference in the of headache attacks lasting hours per month

    change in acute headache medications usage days per month from baseline and each follow-up time point

    Time frame: 12 weeks, 24 weeks, 36 weeks

  3. Difference in the headache pain intensity (NRS)

    changes in the headache severity (based on NRS) between baseline and each follow-up time point

    Time frame: 12 weeks, 24 weeks, 36 weeks

  4. Difference in the number of days with acute headache medication intake per month

    change in acute headache medications usage days per month from baseline and each follow-up time point

    Time frame: 12 weeks, 24 weeks, 36 weeks

  5. Difference in the Migraine Disability Assessment

    changes in the Migraine Disability Assessmen between baseline and each follow-up time point. Title: Migraine Disability Assessmen Maximum value:450 Minimum value:0 Higher scores mean: worsen outcome

    Time frame: 12 weeks, 24 weeks, 36 weeks

  6. Difference in the Beck's Depression Inventory

    change in Beck's Depression Inventory between baseline and each follow-up time point Title:Beck's Depression Inventory Maximum value:63 Minimum value:0 Higher scores mean: worsen outcome

    Time frame: 12 weeks, 24 weeks, 36 weeks

  7. Difference in the Hospital Anxiety and Depression Scale

    change in Hospital Anxiety and Depression Scale between baseline and each follow-up time point Title:Hospital Anxiety and Depression Scale Maximum value:21/21 Minimum value:0/0 Higher scores mean:worsen outcome

    Time frame: 12 weeks, 24 weeks, 36 weeks

  8. 30% reduction in migraine days

    ≥ 30% reduction in migraine days between baseline and each follow-up time point

    Time frame: 12 weeks, 24 weeks, 36 weeks

  9. Substance P

    change in Substance P from baasline and each follow-up time point

    Time frame: 12 weeks, 24 weeks, 36 weeks

  10. beta-endorphin

    change in beta-endorphin from baasline and each follow-up time point

    Time frame: 12 weeks, 24 weeks, 36 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Nov 2027, 30 months after the start.

Of 309 non-industry interventional studies with no phase under Migraine Disorders, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 36. This study's planned 30 months is above that.

Counting every sponsor, half of 358 studies reached it within 15 months; a quarter within 7 and three quarters within 34.

Primary completion moved once since we started tracking on Sep 25, 2026: Nov 2025 → Nov 2027, on Sep 30, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 2, 2024
First posted
Sep 4, 2024
StartActual
Apr 7, 2025
Primary completionEst.
Nov 1, 2027was Nov 2025
CompletionEst.
Dec 1, 2027
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Nov 1, 2025→Nov 1, 2027
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    Primary completion Nov 1, 2025→Nov 1, 2027
    + 2 other changes: index terms and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06584409
Responsible party
Sponsor
First posted
Sep 4, 2024
Start date
Apr 7, 2025
Primary completion
Nov 1, 2027 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
Sep 30, 2026

Study contacts

Yuan-Chen Liu, M.D.
Contact
jordan810701@gmail.com
886-972199271
Ching-Chun Chung, M.D.
Contact
gracechung1015@gmail.com
886-988566621
Chi-Hsiang Chou, M.D.
principal investigator · Taichung Veterans General Hospital
Chi Sheng Wang, M.D.
study director · Taichung Veterans General Hospital
Huan Yun Wu, M.D.
study director · Taichung Veterans General Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion